Entity

Time filter

Source Type

Lyngby, Denmark

Symphogen is a biotechnology company located in Copenhagen, Denmark that produces recombinant polyclonal antibody drugs for disease treatment and prevention. Their three main areas of therapeutic research are immunoglobulin replacement, cancer, and infectious diseases. The company was founded in 2000 and has patents on a drug discovery platform called Symplex and a drug manufacturing platform called Sympress. Currently, ten drugs are being developed with rozrolimupab being the lead product. Wikipedia.


Patent
Symphogen and Meiji Seika Pharma Co. | Date: 2011-02-18

Provided is a novel antibody having an excellent antibacterial activity against


Patent
Symphogen and Meiji Seika Pharma Co. | Date: 2011-02-18

Provided is a novel antibody having an excellent antibacterial activity against


The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. Nucleic acid segments encoding the anti-RhD rpAb are introduced into the cells by transfection with a library of vectors for site-specific integration. The method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immunoglobulin products.


Patent
Symphogen and Meiji Seika Pharma Co. | Date: 2011-02-18

Provided is a novel antibody having an excellent antibacterial activity against


The present invention provides a structural characterization platform that can be used to assess the stability of a polyclonal cell line during production, as well as batch-to-batch consistency of the final polyclonal products. The structural characterization platform is based on genetic analyses as well as protein characterization techniques that alone or in combination provides the necessary information to characterize the polyclonal cell line and final products. The collection of different homologous proteins to be analyzed with the platform techniques is for example a recombinant polyclonal antibody or a mixture of monoclonal antibodies.

Discover hidden collaborations